Achillion Pharmaceuticals, Inc. (ACHN)
-NasdaqGS 7.93 
0.23(2.99%) Jun 17, 4:00PM EDT
| Prev Close: | 7.70 |
|---|
| Open: | 7.78 |
|---|
| Bid: | N/A |
|---|
| Ask: | 9.00 x 300 |
|---|
| 1y Target Est: | 14.00 |
|---|
| Beta: | 2.07 |
|---|
| Next Earnings Date: | 5-Aug-13 |
|---|
| Day's Range: | 7.74 - 8.05 |
|---|
| 52wk Range: | 5.42 - 11.36 |
|---|
| Volume: | 816,376 |
|---|
| Avg Vol (3m): | 1,006,110 |
|---|
| Market Cap: | 765.69M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.64 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Biotechs Lose Ground As Achillion Takes a Diveat Motley Fool(Sat, Jun 15)
- 5 Stocks Seeing Bullish Options Activityat TheStreet(Thu, Jun 13)
- Commit To Buy Achillion Pharmaceuticals At $5, Earn 20%at Forbes(Wed, Jun 12)
- Achillion to Present at the Wells Fargo 2013 Healthcare ConferenceGlobeNewswire(Wed, Jun 12)
- Insiders Bullish on Certain Holdings of IWCat Forbes(Fri, Jun 7)
- Wednesday 6/5 Insider Buying Report: WCC, ACHNat Forbes(Wed, Jun 5)
- Top Buys by Directors: Liotta's $158.1K Bet on ACHNat Forbes(Wed, Jun 5)
- Achillion Pharmaceuticals Director Buys 20K Shares and 4 Insider Trades to Noteat Wall St. Cheat Sheet(Wed, Jun 5)
- Achillion: Is This Stock For Traders Or For Long Term Investors?at Seeking Alpha(Mon, Jun 3)
- Why the Smart Money Is Bullish on Achillion Pharmaceuticalsat Minyanville(Fri, May 31)
- [video] iPhone Sales In India Near 400,000at CNBC(Fri, May 31)
- Largest option buying in equities so faroptionMONSTER(Fri, May 31)
- The Young And Restless Portfolio: Aggressive Growth Of Over 40% In 5 Monthsat Seeking Alpha(Fri, May 31)
- Achillion Pharmaceuticals' Management Presents at 38th Annual Deutsche Bank Health Care Conference (Transcript)at Seeking Alpha(Thu, May 30)
- Achillion Pharmaceuticals, Inc. - Special Callat Seeking Alpha(Thu, May 30)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 6,300.69 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.65 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.15 |
|---|
| Mean Recommendation*: | 1.8 |
|---|
| PEG Ratio (5 yr expected): | -2.58 |
|---|
Business Summary
Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes anti-infective drug therapies in the United States and internationally.
View More